AstraZeneca: Japan grants orphan drug status to selumetinib
(CercleFinance.com) - AstraZeneca said on Tuesday that Japanese regulators have granted orphan drug status to selumetinib to treat type 1 neurofibromatosis, a rare and debilitating genetic disease.
Japan grants orphan drug status to medicines intended for the treatment of diseases that affect fewer than 50,000 patients, and for which there is a high unmet medical need.
Patients with neurofibromatosis often experience tumours growing along their nerves, causing disfigurement, motor dysfunction, pain, visual impairment and bowel/bladder dysfunction.
Selumetinib is being jointly developed and commercialised with US peer Merck.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Japan grants orphan drug status to medicines intended for the treatment of diseases that affect fewer than 50,000 patients, and for which there is a high unmet medical need.
Patients with neurofibromatosis often experience tumours growing along their nerves, causing disfigurement, motor dysfunction, pain, visual impairment and bowel/bladder dysfunction.
Selumetinib is being jointly developed and commercialised with US peer Merck.
Copyright (c) 2020 CercleFinance.com. All rights reserved.